Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Xbrane Biopharma

14.15 SEK+8.85 %30/10 12:59
Less than 1K followers

XBRANE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+8.85 %
+27.48 %
+41.50 %
+28.64 %
+38.73 %
+34.38 %
-94.97 %
-99.22 %
-97.03 %

Xbrane Biopharma is a biotechnology company focused on the development of biosimilars and biologics. The company is researching new therapies that can improve patient outcomes and quality of life. The products are used in the treatment of prostate cancer and endometriosis, as well as rare and serious eye diseases. Xbrane Biopharma was founded in 2008 and is headquartered in Solna, Sweden.

Read more
Market cap
291.57M SEK
Turnover
7.2M SEK
Revenue
152.35M
EBIT %
-18.54 %
P/E
176.88
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Forum discussions
Quite a struggle. A trainwreck, as they would say across the pond. Once again, additional information must be provided to the FDA, and the BLA has been withdrawn. An additional delay of approximately 6–12 months is expected AND even more capital may potentially be needed. For fun...
4/23/2024, 7:25 AM
by vesuri
7
xbrane.com » Xbrane and STADA partner with Valorum Biologics to commercialize... XBRANE AND STADA PARTNER WITH VALORUM BIOLOGICS TO COMMERCIALIZE RANIBIZUMAB BIOSIMILAR CANDIDATE IN THE US Based on this, could one think that obtaining FDA approval looks quite promising?
5/10/2024, 7:13 AM
by OSAKEURPO
4
Xbrane received FDA approval for its biosimilar: Bioteknikbolaget rusar 50 procent på FDA-besked
10/28/2026, 8:52 AM
by Kimmo Kautio
3
Xbrane warns that it will be insolvent in a couple of months if the desired financing solutions are not reached and the company does not manage to out-license the Xdivane™ and/or XB003 candidates by the end of October. As communicated on 1 August 2024 and given the previously communicated...
8/12/2024, 11:38 AM
by vesuri
3
It’s frustrating when the reverse split isn’t properly taken into account. But that company’s journey is still not amounting to anything.
10/22/2025, 12:03 PM
by Clark kent
1
It’s hard to see any profitable future for this Ximluci. From what I’ve researched, off-label Bevacizumab is still cheaper, and on the other hand, aflibercept and faricimab are better and longer-acting. There simply isn’t a market niche.
5/10/2024, 7:34 AM
by Clark kent
1
The share price has started to wake up in recent days. Apparently in anticipation of FDA approval in April.
4/8/2024, 3:07 PM
by OSAKEURPO
1
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
30/10
2026

Interim report Q3'26

19/2
2027

Annual report '26

3/5
2027

Interim report Q1'27

Xbrane Biopharma, Webcast, Q3'26
Webcast2026-10-30 09:00

Xbrane Biopharma, Webcast, Q3'26

Xbrane Biopharma
Regulatory press release2026-10-30 08:00

Xbrane Biopharma publicerar Delårsrapport januari-September 2026

Xbrane Biopharma
Regulatory press release2026-10-30 08:00

Xbrane Biopharma releases Interim Report for January-September 2026

Xbrane Biopharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-10-28 11:50

Redeye: Xbrane Biopharma: Lucamzi approved by the FDA

Xbrane Biopharma
Regulatory press release2026-10-27 15:40

FDA godkänner Lucamzi™ - biosimilar till Lucentis®

Xbrane Biopharma
Regulatory press release2026-10-27 15:40

FDA approves Lucamzi™ - biosimilar to Lucentis®

Xbrane Biopharma
Press release2026-10-23 08:00

Inbjudan till presentation av Xbrane Biopharmas delårsrapport januari – september 2026 den 30 oktober 2026

Xbrane Biopharma
Press release2026-10-23 08:00

Invitation to presentation of Xbrane Biopharma’s interim report January – September 2026 on October 30, 2026

Xbrane Biopharma
Press release2026-10-13 18:48

Redeye: Xbrane Biopharma: Xdivane pivotal study fully recruited

Xbrane Biopharma
Press release2026-10-13 08:00

Xbrane meddelar full patientrekrytering till den registreringsgrundande kliniska studien för Xdivane™

Xbrane Biopharma
Press release2026-10-13 08:00

Xbrane Announces Full Recruitment of Pivotal Clinical Trial for Xdivane™

Xbrane Biopharma
Regulatory press release2026-10-09 08:00

XBRANE BIOPHARMA PRESENTERAR VALBEREDNINGEN

Xbrane Biopharma
Regulatory press release2026-10-09 08:00

XBRANE BIOPHARMA PRESENTS THE NOMINATION COMMITTEE

Xbrane Biopharma
Press release2026-07-26 13:25

Redeye: Xbrane Biopharma (Q2 review): Crucial months ahead, BsUFA in October

Xbrane Biopharma
Xbrane Biopharma, Webcast, Q2'26
Webcast2026-07-17 09:00

Xbrane Biopharma, Webcast, Q2'26

Xbrane Biopharma
Regulatory press release2026-07-17 08:30

Xbrane Biopharma publicerar Delårsrapport januari-juni 2026

Xbrane Biopharma
Regulatory press release2026-07-17 08:30

Xbrane Biopharma releases Interim Report for January-June 2026

Xbrane Biopharma
Regulatory press release2026-06-11 20:00

Xbrane Biopharma AB and JOINN Biologics US Inc. Enter Strategic Partnership to Develop Xdarzane – Xbrane´s Biosimilar Candidate to Darzalex® (Daratumumab)

Xbrane Biopharma
Regulatory press release2026-06-11 20:00

Xbrane Biopharma AB och JOINN Biologics US Inc. ingår strategiskt partnerskap för att utveckla Xdarzane – Xbranes biosimilarkandidat till Darzalex® (daratumumab)

Xbrane Biopharma
Regulatory press release2026-06-03 18:00

Xbrane Biopharma AB (publ) (”Xbrane” eller ”Bolaget”) (Nasdaq Stockholm: XBRANE) erhåller FDA beslutsdatum (BsUFA) den 29 oktober 2026 för sin biosimilarkandidat till LUCENTIS® (ranibizumab)

Xbrane Biopharma